Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled study of topiroxostat tablets in gout with hyperuricemia
CTR20263894Phase 3Active
- Sponsor
- Hunan Xianshi Pharmaceutical
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of topiroxostat in gout, hyperuricemia, sponsored by Hunan Xianshi Pharmaceutical. Started Oct 2026; status: active.
02
Drugs
topiroxostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20263894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263894.